Search results
Results from the WOW.Com Content Network
AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All the major market averages finished higher for the week, with the S&P 500 gaining 2.5%, the Dow Jones Industrial average ending up 1.8% and the Nasdaq climbing north of 4%.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of $71.5 million in 2013. [5] In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020. [6] In June 2015, the company acquired Cord Blood Registry for $700 million. [7] In 2014, AMAG acquired Lumara Health, formerly KV ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us